Quadrature Capital’s Amneal Pharmaceuticals AMRX Stock Holding History

Quadrature Capital’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-20,336	Closed	-$169K	–	1007
2024 Q3	$169K	Buy	+20,336	New	+$159K	﹤0.01%	798
2021 Q3	–	Sell	-37,211	Closed	-$191K	–	675
2021 Q2	$191K	Sell	37,211 -123,590	-77%	-$702K	0.01%	832
2021 Q1	$1.08M	Buy	+160,801	New	+$891K	0.05%	298
2020 Q3	–	Sell	-88,300	Closed	-$420K	–	717
2020 Q2	$420K	Buy	88,300 +75,500	+590%	+$311K	0.05%	417
2020 Q1	$44K	Buy	+12,800	New	+$54.2K	0.01%	484
2018 Q4	–	Sell	-14,590	Closed	-$324K	–	451
2018 Q3	$324K	Buy	+14,590	New	+$307K	0.03%	440

Other funds holding AMRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Quadrature Capital's AMRX Position: Q4 2024 in Review

Quadrature Capital sold out of Amneal Pharmaceuticals (AMRX) in Q4 2024, closing a stake of 20,336 shares — an estimated $169K sold.

Quadrature Capital first reported a position in AMRX in Q3 2018 and held it in 6 quarters. The position peaked at $1.08M in Q1 2021. 199 funds tracked by Wall St. Rank hold AMRX as of Q4 2024.

Quadrature Capital reported no remaining Amneal Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Quadrature Capital sold 20,336 Amneal Pharmaceuticals shares in Q4 2024, an estimated $169K.
Quadrature Capital first reported a position in Amneal Pharmaceuticals in Q3 2018 and held it in 6 quarters.
Quadrature Capital's Amneal Pharmaceuticals position peaked at $1.08M in Q1 2021.
199 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2024.

Based on Quadrature Capital's 13F filing for Q4 2024, filed 13 Feb 2025.